Evidence map›Paper›PMID 42589680›Full record

ArticleInternational journal of molecular sciences2026

Comparative Protective Effects of Anakinra and Tocilizumab in Experimental Ocular Ischemic Syndrome.

Shavkatbek Karimov, Esra Tuba Sezgin, Renad Mammadov, Bahadir Suleyman, Kamandar Yaqudov, Gulce Naz Yazici, Taha Abdulkadir Coban, Halis Suleyman, Kemal Bayrakceken

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shavkatbek KarimovDepartment of Ophthalmology, Mengücek Gazi Training and Research Hospital, Erzincan 24100, Turkey.
Esra Tuba SezginAnesthesia Program, Vocational School of Health Services, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.ORCID 0000-0003-3491-9798
Renad MammadovDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
Bahadir SuleymanDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.ORCID 0000-0001-5795-3177
Kamandar YaqudovDepartment of Pharmacology, Azerbaijan Medical University, Baku AZ1000, Azerbaijan.
Gulce Naz YaziciDepartment of Histology and Embryology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.
Taha Abdulkadir CobanDepartment of Medical Biochemistry, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.ORCID 0000-0003-1711-5499
Halis SuleymanDepartment of Pharmacology, Faculty of Medicine, Erzincan Binali Yıldırım University, Erzincan 24100, Turkey.ORCID 0000-0002-9239-4099
Kemal BayrakcekenDepartment of Ophthalmology, Mengücek Gazi Training and Research Hospital, Erzincan 24100, Turkey.ORCID 0000-0001-9550-1358

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular ischemic syndrome (OIS) is a vision-threatening disorder characterized by retinal ischemia, oxidative stress, and inflammation. In this study, the protective effects of anakinra, an interleukin-1 receptor antagonist, were investigated and compared with those of tocilizumab, an interleukin-6 receptor antagonist. Twenty-four male Wistar rats were randomly assigned to four groups (

Indexed as

Antibodies, Monoclonal, HumanizedInterleukin 1 Receptor Antagonist ProteinIschemiaReperfusion InjuryAnimalsDisease Models, AnimalInterleukin-1betaInterleukin-6MaleMalondialdehydeOxidative StressRatsRats, WistarRetinaSuperoxide DismutaseTumor Necrosis Factor-alphaAntibodies, Monoclonal, HumanizedInterleukin-1betaInterleukin 1 Receptor Antagonist ProteinInterleukin-6MalondialdehydeSuperoxide DismutasetocilizumabTumor Necrosis Factor-alphaanakinraIL-1βIL-6inflammationischemia–reperfusion injuryocular ischemic syndromeoxidative stressretinal ischemiatocilizumab

Identifiers

PMID42589680
PMCPMC13467194

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.